These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 25096555

  • 21. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
    Arosio M, Arnaldi G, Gasco V, Giavoli C, Puxeddu E, Vettor R, Ambrosio MR, Gallinari P, Zouater H, Fedeli P, Ferone D.
    J Endocrinol Invest; 2021 Feb; 44(2):327-337. PubMed ID: 32507990
    [Abstract] [Full Text] [Related]

  • 22. One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP, Birkholz-Walerzak D, Szalecki M, Walczak M, Galesanu C, Metreveli D, Khan-Boluki J, Schuck E.
    Biol Ther; 2014 Dec; 4(1-2):1-13. PubMed ID: 24676989
    [Abstract] [Full Text] [Related]

  • 23. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.
    Root AW, Kemp SF, Rundle AC, Dana K, Attie KM.
    J Pediatr Endocrinol Metab; 1998 Dec; 11(3):403-12. PubMed ID: 11517956
    [Abstract] [Full Text] [Related]

  • 24. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
    Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S.
    Ther Adv Endocrinol Metab; 2013 Feb; 4(1):3-11. PubMed ID: 23515245
    [Abstract] [Full Text] [Related]

  • 25. Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study.
    Lämmer C, Backeljauw P, Tauber M, Kanumakala S, Loche S, Otfried Schwab K, Pfäffle R, Höybye C, Lundberg E, Dahlgren J, Ek AE, Battelino T, Kriström B, Esmael A, Zabransky M.
    Ther Adv Endocrinol Metab; 2024 Feb; 15():20420188241264343. PubMed ID: 39371577
    [Abstract] [Full Text] [Related]

  • 26. The long-term growth, cost-effectiveness, and glycemic effects of growth hormone therapy on children born small for gestational age over 10 years: a retrospective cohort study.
    Al Khalifah RA, Alhakami A, AlRuthia Y, Al Sarraj HZ, Abulqasim J, Al-Rasheedi A, NurHussen A, Naji A.
    J Pediatr Endocrinol Metab; 2022 Nov 25; 35(11):1357-1368. PubMed ID: 36203313
    [Abstract] [Full Text] [Related]

  • 27. Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults).
    Höybye C, Beck-Peccoz P, Murray RD, Simsek S, Stalla G, Strasburger CJ, Urosevic D, Zouater H, Johannsson G.
    Pituitary; 2021 Aug 25; 24(4):622-629. PubMed ID: 33742320
    [Abstract] [Full Text] [Related]

  • 28. No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
    Beck-Peccoz P, Höybye C, Murray RD, Simsek S, Zabransky M, Zouater H, Stalla G.
    BMC Endocr Disord; 2019 Dec 11; 19(1):138. PubMed ID: 31829160
    [Abstract] [Full Text] [Related]

  • 29. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L, Antoniazzi F, Giavoli C, Bona G, Aversa T, Greggio NA, Guazzarotti L, Minelli R, Perrone L, Persani L, Pozzobon G, Ragusa L, Stagi S, Tornese G, Zecchino C, Gallinari P, Zouater H, Fedeli P, Zucchini S.
    J Endocrinol Invest; 2021 Mar 11; 44(3):493-503. PubMed ID: 32557273
    [Abstract] [Full Text] [Related]

  • 30. Beyond Growth Hormone: Association of Short Stature Types and Growth Hormones With Scoliosis.
    Hong H, Hu J, Xu H, Xia D, Pan X, Chen X, Guo Q, Zhang S, Chen J, Wu Y, Leng H, Zhang X, Wang X, Huang C.
    Spine (Phila Pa 1976); 2024 Feb 15; 49(4):221-231. PubMed ID: 37871182
    [Abstract] [Full Text] [Related]

  • 31. [Analysis of the influencing factors of recombinant human growth hormone effect in the children with Turner syndrome].
    Li J, Wu W, Liang Y, Luo XP.
    Zhonghua Er Ke Za Zhi; 2018 Nov 02; 56(11):866-870. PubMed ID: 30392213
    [Abstract] [Full Text] [Related]

  • 32. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis.
    Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA.
    J Clin Endocrinol Metab; 2009 Oct 02; 94(10):3721-30. PubMed ID: 19584188
    [Abstract] [Full Text] [Related]

  • 33. Treatment of Isolated Idiopathic Growth Hormone Deficiency in Children and Thyroid Function: Is the Need for LT4 Supplementation a Concern in Long-Term Therapy?
    Salazar D, Rey V, Neves JS, Esteves C, Santos Silva R, Ferreira S, Costa C, Carvalho D, Castro-Correia C.
    Cureus; 2022 Jan 02; 14(1):e21722. PubMed ID: 35251796
    [Abstract] [Full Text] [Related]

  • 34. The pre-treatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease.
    Witkowska-Sędek E, Labochka D, Majcher A, Pyrżak B.
    Cent Eur J Immunol; 2018 Jan 02; 43(1):69-75. PubMed ID: 29736148
    [Abstract] [Full Text] [Related]

  • 35. Comparison of growth hormone treatment in patients with idiopathic short stature and idiopathic growth hormone deficiency.
    Kim SA, Choe YR, Yang EM, Kim CJ.
    Chonnam Med J; 2014 Aug 02; 50(2):63-6. PubMed ID: 25229018
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A, González L, Gunczler P, Lanes R.
    J Pediatr Endocrinol Metab; 2012 Aug 02; 25(7-8):651-7. PubMed ID: 23155689
    [Abstract] [Full Text] [Related]

  • 39. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
    Binder G, Baur F, Schweizer R, Ranke MB.
    J Clin Endocrinol Metab; 2006 Feb 02; 91(2):659-64. PubMed ID: 16291706
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.